Literature DB >> 16401314

Examining the relationships between the Pro12Ala variant in PPARG and Type 2 diabetes-related traits in UK samples.

E Zeggini1, J R C Parkinson, S Halford, K R Owen, M Walker, G A Hitman, J C Levy, M J Sampson, T M Frayling, A T Hattersley, M I McCarthy.   

Abstract

AIMS: The Pro12Ala polymorphism in the PPARG gene alters amino acid sequence and has shown consistent association with susceptibility to Type 2 diabetes in several populations. The present study makes use of large, well-characterized case-control resources to enhance understanding of this susceptibility effect by examining related traits, such as body mass index (BMI), waist-hip ratio and age at diagnosis.
METHODS: The Pro12Ala variant was genotyped in two UK case samples, ascertained for positive family history and/or early onset of Type 2 diabetes (combined n=971); and in 1257 ethnically matched control subjects.
RESULTS: There were significant associations of the Pro12Ala single nucleotide polymorphism (SNP) genotypes with diabetes in both case-control comparisons (P=0.025 and P=0.039). Comparing individuals homozygous for the Pro allele, with those carrying an Ala allele, the combined odds ratio for diabetes was 1.40 (95% CIs, 1.12-1.76, P=0.0031). There was no association between the variant and either waist-hip ratio or age at diagnosis. Proline homozygosity was associated with increased BMI in one patient group (P=0.013) and decreased BMI in the other (P=0.038).
CONCLUSIONS: This study confirms that variation within PPARG influences susceptibility to Type 2 diabetes in UK samples. However, the relationship between PPARG variation and BMI is more complex, and studies in much larger sample sets will be required to more precisely characterize the effect of this variant on adiposity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16401314     DOI: 10.1111/j.1464-5491.2005.01717.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  7 in total

1.  Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.

Authors:  Jose C Florez; Kathleen A Jablonski; Maria W Sun; Nick Bayley; Steven E Kahn; Harry Shamoon; Richard F Hamman; William C Knowler; David M Nathan; David Altshuler
Journal:  J Clin Endocrinol Metab       Date:  2007-01-09       Impact factor: 5.958

2.  The functional "KL-VS" variant of KLOTHO is not associated with type 2 diabetes in 5028 UK Caucasians.

Authors:  Rachel M Freathy; Michael N Weedon; David Melzer; Beverley Shields; Graham A Hitman; Mark Walker; Mark I McCarthy; Andrew T Hattersley; Timothy M Frayling
Journal:  BMC Med Genet       Date:  2006-06-05       Impact factor: 2.103

Review 3.  Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?

Authors:  Carla Pollastro; Carmela Ziviello; Valerio Costa; Alfredo Ciccodicola
Journal:  PPAR Res       Date:  2015-06-15       Impact factor: 4.964

4.  PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis.

Authors:  Negar Sarhangi; Farshad Sharifi; Leila Hashemian; Maryam Hassani Doabsari; Katayoun Heshmatzad; Marzieh Rahbaran; Seyed Hamid Jamaldini; Hamid Reza Aghaei Meybodi; Mandana Hasanzad
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

5.  Impact of the Pro12Ala polymorphism of the PPAR-Gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients.

Authors:  S Ereqat; A Nasereddin; K Azmi; Z Abdeen; R Amin
Journal:  PPAR Res       Date:  2009-10-25       Impact factor: 4.964

6.  PPARγ2 polymorphism and human health.

Authors:  Weimin He
Journal:  PPAR Res       Date:  2009-04-16       Impact factor: 4.964

7.  Combining information from common type 2 diabetes risk polymorphisms improves disease prediction.

Authors:  Michael N Weedon; Mark I McCarthy; Graham Hitman; Mark Walker; Christopher J Groves; Eleftheria Zeggini; N William Rayner; Beverley Shields; Katharine R Owen; Andrew T Hattersley; Timothy M Frayling
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.